Nurix Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Nurix Therapeutics

09/02/2024 21:30

* Nurix Therapeutics Inc  NRIX.OQ   NRIX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
12 (estimated) for the period ending November 30 2023
    * The San Francisco California-based  company is expected to
report a 228.2% increase in revenue to $22.262 million from
$6.78 million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Nurix Therapeutics Inc
is for
a loss of 57 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $26.50​, above​ its last closing price
of $8.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Aug. 31 2023  -0.78       -0.76      -0.68     Beat    10
 May. 31 2023  -0.49       -0.56      -0.45     Beat    19.6
 Feb. 28 2023  -0.86       -0.87      -0.75     Beat    13.6​
 Nov. 30 2022  -0.83       -0.79      -0.87     Missed  -10.3
 ​​Aug.        -0.96       -0.98      -0.90     Beat    7.7
 31 2022                                                
 May. 31 2022  -0.98       -0.99      -1.01     Missed  -2.4​
 Feb. 28 2022  -0.89       -0.88      -0.95     Missed  -8.5
 Nov. 30 2021  -0.69       -0.69      -0.85     Missed  -22.5
 This summary was machine generated February 9 at 21:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)